Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?

被引:15
|
作者
Abas, Abdul Hawil [1 ]
Marfuah, Siti [1 ]
Idroes, Rinaldi [2 ]
Kusumawaty, Diah [3 ]
Fatimawali [4 ]
Park, Moon Nyeo [5 ]
Siyadatpanah, Abolghasem [6 ]
Alhumaydhi, Fahad A. [7 ]
Mahmud, Shafi [8 ]
Tallei, Trina Ekawati [1 ]
Bin Emran, Talha [9 ]
Kim, Bonglee [5 ]
机构
[1] Sam Ratulangi Univ, Fac Math & Nat Sci, Dept Biol, Manado 95115, North Sulawesi, Indonesia
[2] Univ Syiah Kuala, Fac Math & Nat Sci, Dept Pharm, Banda Aceh 23111, Aceh, Indonesia
[3] Univ Pendidikan Indonesia, Fac Math & Nat Sci Educ, Dept Biol, Bandung 40154, West Java, Indonesia
[4] Sam Ratulangi Univ, Fac Math & Nat Sci, Pharm Study Program, Manado 95115, North Sulawesi, Indonesia
[5] Kyung Hee Univ, Coll Korean Med, Seoul 05253, South Korea
[6] Birjand Univ Med Sci, Ferdows Sch Paramed & Hlth, Birjand 9717853577, Iran
[7] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 52571, Saudi Arabia
[8] Australian Natl Univ, John Curtin Sch Med Res, Dept Genome Sci, Canberra, ACT 0200, Australia
[9] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh
来源
MOLECULES | 2022年 / 27卷 / 07期
基金
新加坡国家研究基金会;
关键词
COVID-19; SARS-CoV-2; Omicron; natural immunity; hybrid immunity; MAIN PROTEASE; TRANSMISSION; MECHANISMS; INFECTION; VACCINES; FUTURE; ORIGIN;
D O I
10.3390/molecules27072221
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic is still ongoing, with no signs of abatement in sight. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of this pandemic and has claimed over 5 million lives, is still mutating, resulting in numerous variants. One of the newest variants is Omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated. As a result, many believe that Omicron provides a natural vaccination, which is the first step toward ending the COVID-19 pandemic. Based on published research and scientific evidence, we review and discuss how the end of this pandemic is predicted to occur as a result of Omicron variants being surpassed in the community. In light of the findings of our research, we believe that it is most likely true that the Omicron variant is a natural way of vaccinating the masses and slowing the spread of this deadly pandemic. While the mutation that causes the Omicron variant is encouraging, subsequent mutations do not guarantee that the disease it causes will be less severe. As the virus continues to evolve, humans must constantly adapt by increasing their immunity through vaccination.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Value of Laboratory Indicators in Predicting Pneumonia in Symptomatic COVID-19 Patients Infected with the SARS-CoV-2 Omicron Variant
    Zhu, Kongbo
    Ma, Shaolei
    Chen, Hui
    Xie, Jianfeng
    Huang, Dan
    Fu, Cuiping
    Ma, Genshan
    Huang, Yingzi
    INFECTION AND DRUG RESISTANCE, 2023, 16 : 1159 - 1170
  • [32] Viral dynamics of the SARS-CoV-2 Omicron Variant among household contacts with 2 or 3 COVID-19 vaccine doses
    Kandel, Christopher
    Lee, Yaejin
    Taylor, Maureen
    Llanes, Andrea
    McCready, Janine
    Crowl, Gloria
    Powis, Jeff
    Li, Angel Xinliu
    Shigayeva, Altynay
    Yip, Lily
    Katz, Kevin
    Kozak, Robert
    Mubareka, Samira
    McGeer, Allison
    JOURNAL OF INFECTION, 2022, 85 (06) : 666 - 670
  • [33] Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination-Evidence Synthesis and Implications for New COVID-19 Vaccines
    Spinardi, Julia R. R.
    Srivastava, Amit
    BIOMEDICINES, 2023, 11 (02)
  • [34] COVID-19 Reinfection in a Healthcare Worker; Is There a Definitive Immunity Against SARS-CoV-2?
    Ahmadi, Sayyed Reza
    Ardakani, Saeideh Anvari
    Kalani, Navid
    Habibzadeh, Seyed Reza
    Moradi, Elnaz Vafadar
    Foroughian, Mahdi
    FRONTIERS IN EMERGENCY MEDICINE, 2021, 5 (02):
  • [35] Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway
    STALCRANTZ, J. E. A. N. E. T. T. E.
    KRISTOFFERSEN, A. N. J. A. B. R. A. T. H. E. N.
    BOAS, H. A. K. O. N.
    VENETI, L. A. M. P. R. I. N. I.
    SEPPALA, E. L. I. N. A.
    AASAND, N. I. N. A.
    HUNGNES, O. L. A., V
    KVALE, R. E. I. D. A. R.
    BRAGSTAD, K. A. R. O. L. I. N. E.
    BUANES, E. I. R. I. K. A. L. N. E. S.
    WHITTAKER, R. O. B. E. R. T.
    SCANDINAVIAN JOURNAL OF PUBLIC HEALTH, 2022, 50 (06) : 676 - 682
  • [36] Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies
    Dhama, Kuldeep
    Nainu, Firzan
    Frediansyah, Andri
    Yatoo, Mohd Iqbal
    Mohapatra, Ranjan K.
    Chakraborty, Sandip
    Zhou, Hao
    Islam, Md. Rabiul
    Mamada, Sukamto S.
    Kusuma, Hendrix Indra
    Rabaan, Ali A.
    Alhumaid, Saad
    Al Mutair, Abbas
    Iqhrammullah, Muhammad
    Al-Tawfiq, Jaffar A.
    Al Mohaini, Mohammed
    Alsalman, Abdulkhaliq J.
    Tuli, Hardeep Singh
    Chakraborty, Chiranjib
    Harapan, Harapan
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2023, 16 (01) : 4 - 14
  • [37] Endogenous piRNAs Can Interact with the Omicron Variant of the SARS-CoV-2 Genome
    Rakhmetullina, Aizhan
    Akimniyazova, Aigul
    Niyazova, Togzhan
    Pyrkova, Anna
    Kamenova, Saltanat
    Kondybayeva, Aida
    Ryskulova, Alma-Gul
    Ivashchenko, Anatoliy
    Zielenkiewicz, Piotr
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2023, 45 (04) : 2950 - 2964
  • [38] SARS-CoV-2 and COVID-19 for the ophthalmologist
    Brandao-de-Resende, Camilo
    Diniz-Filho, Alberto
    de Almeida Brito, Fabiano
    Vasconcelos-Santos, Daniel Vitor
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 49 (01) : 70 - 80
  • [39] Omicron: A highly transmissible SARS-CoV-2 variant
    Rahimi, Farid
    Abadi, Amin Talebi Bezmin
    GENE REPORTS, 2022, 27
  • [40] Omicron: A SARS-CoV-2 variant of real concern
    Gattinger, Pia
    Tulaeva, Inna
    Borochova, Kristina
    Kratzer, Bernhard
    Trapin, Doris
    Kropfmuller, Anna
    Pickl, Winfried F.
    Valenta, Rudolf
    ALLERGY, 2022, 77 (05) : 1616 - 1620